Navigation Links
Regeneron and Sanofi Announce Plan to Use Priority Review Voucher For Alirocumab U.S. FDA Submission
Date:7/30/2014

rally identified by the words "expects", "anticipates", "believes", "intends", "estimates", "plans" and similar expressions.  Although Sanofi's management believes that the expectations reflected in such forward-looking statements are reasonable, investors are cautioned that forward-looking information and statements are subject to various risks and uncertainties, many of which are difficult to predict and generally beyond the control of Sanofi, that could cause actual results and developments to differ materially from those expressed in, or implied or projected by, the forward-looking information and statements.  These risks and uncertainties include among other things, the uncertainties inherent in research and development, future clinical data and analysis, including post marketing, decisions by regulatory authorities, such as the FDA or the EMA, regarding whether and when to approve any drug, device or biological application that may be filed for any such product candidates as well as their decisions regarding labelling and other matters that could affect the availability or commercial potential of such product candidates, the absence of guarantee that the product candidates if approved will be commercially successful, the future approval and commercial success of therapeutic alternatives, the Group's ability to benefit from external growth opportunities, trends in exchange rates and prevailing interest rates, the impact of cost containment policies and subsequent changes thereto, the average number of shares outstanding as well as those discussed or identified in the public filings with the SEC and the AMF made by Sanofi, including those listed under "Risk Factors" and "Cautionary Statement Regarding Forward-Looking Statements" in Sanofi's annual report on Form 20-F for the year ended December 31, 2013.  Other than as required by applicable law, Sanofi does not undertake any obligation to update or revise any forward-looking information or statem
'/>"/>
SOURCE Regeneron Pharmaceuticals, Inc.
Copyright©2014 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology technology :

1. Regeneron to Report Second Quarter 2014 Financial and Operating Results and Host Conference Call and Webcast on August 5, 2014
2. Regenerons Chief Executive Officer and Chief Scientific Officer named "Management Team of the Year" by Scrip Intelligence
3. Regeneron Named Top Employer in the Global Biopharmaceutical Industry for the Second Year in a Row
4. After 18 Months On the U.S. Market, Regenerons Eylea Captures One-Fifth of First-Line Intravitreal Pharmacotherapy Share Among Wet Age-Related Macular Degeneration (AMD) Patients
5. Zacks Investment Ideas feature highlights: Market Vectors Biotech ETF, iShares Nasdaq Biotechnology ETF, Regeneron, Celgene and First Trust Amex Biotechnology Index Fund
6. Regeneron Reports First Quarter 2013 Financial and Operating Results
7. Regeneron Pharmaceuticals’ Industrial Operations & Product Supply Site Receives International Recognition for Operational Excellence
8. Sanofi and Regeneron Launch Comprehensive Phase 3 Clinical Program With LDL Cholesterol-Lowering PCSK9 Antibody
9. Sanofi and Regeneron Announce Publication of Positive Phase 2 Results for Lipid-Lowering PCSK9 Antibody in The Lancet
10. Regeneron Announces March 2012 Investor Conference Presentations
11. Regeneron Announces Presentation at the Leerink Swann 2012 Global Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/21/2014)... Nov. 20, 2014 Polaris Group announced ... in its Phase 1 trial of ADI-PEG 20 ... treatment of malignant pleural mesothelioma (MPM) and non-squamous ... clinical trials on ADI-PEG 20, both as monotherapy ... treatment of several other indications, including breast cancer, ...
(Date:11/21/2014)... ON , Nov. 20, 2014 /PRNewswire/ - BIOREM Inc. (TSXV: BRM) ... and nine month periods ended September 30, 2014.  Biorem,s complete 2014 ... ( www.sedar.com ). Financial Summary:Three-months ended September ... except per share data) , 2014 , ... 2,282 , 5,281 , 6,715 ...
(Date:11/18/2014)... November 17, 2014 Cirrascale ... architecture blade-based and rackmount computing infrastructure, today announced ... dual-GPU accelerator throughout its GPU-enabled blade server and ... the company’s latest proprietary 80-lane Gen3 PCIe switch-enabled ... NVIDIA Tesla K80 dual-GPU accelerator cards in a ...
(Date:11/18/2014)... (PRWEB) November 18, 2014 Alanda ... and Transparency Reporting solutions, announced today that a ... using its Consummate Provider™ solution in both the ... a Global, SaaS based, Data Quality remediation portal, ... their third party Providers improve their ability to ...
Breaking Biology Technology:Polaris Group Announces Treatment of First Patient in Phase 1 Study of ADI-PEG 20 plus Pemetrexed and Cisplatin in Malignant Pleural Mesothelioma And Non-Squamous Non-Small Cell Lung Carcinoma 2Biorem Reports Third Quarter Results 2Biorem Reports Third Quarter Results 3Cirrascale® Expands Multi-GPU Peering Solutions with Support for New NVIDIA Tesla K80 Dual-GPU Accelerators 2Cirrascale® Expands Multi-GPU Peering Solutions with Support for New NVIDIA Tesla K80 Dual-GPU Accelerators 3Alanda Software Completes Successful Implementation of Global Data Quality & Vendor Management Solution for Top Tier Global Biopharmaceutical Company 2
... ForteBio(R), Inc., a leading supplier of label-free technology ... products, announced today that it has launched two ... small molecule and fragment screening; and the Octet ... instruments will debut this week at the 2009 ...
... , WASHINGTON, June 22 Pharmaceutical ... Tauzin today issued the following statement regarding today,s AARP-White House ... the strong support of AARP, we believe this agreement will ... the legislative efforts to reform our troubled health care system. ...
... in consumer probiotics expands into livestock industry with Direct ... June 22 Ganeden Biotech, Inc., the largest seller ... launch of GanPro(TM), an all-natural animal feed additive containing ... support gut health and naturally promote feed conversion in ...
Cached Biology Technology:ForteBio Launches Two Revolutionary High-Throughput, Label-Free Instruments: The Octet(R) RED384 and the Octet QK384 2ForteBio Launches Two Revolutionary High-Throughput, Label-Free Instruments: The Octet(R) RED384 and the Octet QK384 3PhRMA Statement on AARP-White House Press Conference 2Ganeden Biotech Introduces GanPro(TM) Direct-Fed Microbial for Livestock 2
(Date:11/5/2014)... professor of biology in the UTSA College of ... nation selected to receive a two-year $300,00 National ... Research (EAGER). The funding supports President Obama,s BRAIN ... create new technology that will demystify complex brain ... in neuroscience are broken into the interactions of ...
(Date:11/4/2014)... School of Medicine announced today that it is ... by the Bill & Melinda Gates Foundation. ... and Reproductive Sciences; and Vice Chair of Research ... Medicine will pursue an innovative global health and ... Assess Fetal Neurodevelopment.", Grand Challenges Explorations (GCE) funds ...
(Date:11/4/2014)...   Neurotechnology , a provider of high-precision ... version of its fingerprint matching algorithm has achieved ... evaluation organized by NIST. The MINEX test measures ... 378 fingerprint standard template format. MINEX compliance is ... the United States and ...
Breaking Biology News(10 mins):UTSA biology professor awarded $300,000 NSF grant for brain research 2UTSA biology professor awarded $300,000 NSF grant for brain research 3Temple University School of Medicine receives Grand Challenges Explorations grant 2Neurotechnology Places Second in Ongoing MINEX Ranking for Fingerprint Matching Algorithms 2Neurotechnology Places Second in Ongoing MINEX Ranking for Fingerprint Matching Algorithms 3
... Nearly 90 percent of children and adults with a ... no evidence of cancer after receiving a novel, personalized ... pilot studies of bioengineered T cells that attack leukemia, ... 28 days after treatment. In all, 27 patients received ...
... international project has developed a free and open public ... and contentious world of gene patenting. In a ... published in this week,s Nature Biotechnology journal, ... keep up with the rapid explosion in information and ...
... Sophisticated recent experiments with ultrashort laser pulses support the ... algae, and some bacteria efficiently gather light to fuel ... mechanisms remain obscure, and the exact role that quantum ... than was once thought, according to an Overview Article ...
Cached Biology News:T cell immunotherapy: Promising results in children and adults with leukemia 2T cell immunotherapy: Promising results in children and adults with leukemia 3Who's patenting whose genome? 2Who's patenting whose genome? 3Quantum effects help cells capture light, but the details are obscure 2
... a positive control for ChIP assays. Efficient ... vivo is a crucial step for the ... is probably the most important parameter. Two ... should be taken into account: first, an ...
... Major Science MS 300V (Cat. No. MP-300V) ... to meet most electrophoresis needs in a ... Science MS 300V power supply provides ... used in electrophoresis. 4 pairs of terminator ...
Rab GDP dissociation inhibitor beta...
... Scientific has a long and outstanding ... apparatus. Several years ago we became ... microdispenser was being modified to inject ... by redesigning the microdispenser to eliminate ...
Biology Products: